Health Care/Hospital

Wellysis and Artella Solutions Launch Innovative Remote Cardiac Monitoring Service in the US.

SEOUL, South Korea, March 8, 2024 /PRNewswire/ -- Wellysis, a digital healthcare company spun off from Samsung, has announced the launch of remote cardiac monitoring service in the US in partnership with Artella Solutions (ARTELLA). Sepand...

2024-03-08 22:00 2284

TransThera Announced Global Phase 3 Clinical Trial for Cholangiocarcinoma Authorized in the European Union and Orphan Drug Designation for Tinengotinib to Treat Biliary Tract Cancer Granted by European Medicines Agency

NANJING, China and GAITHURSBURG, Md., March 8, 2024 /PRNewswire/ -- TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announced that the randomized, controlled, global multicenter Phase 3 trial (FIRST-308) of tinengotinib versus ph...

2024-03-08 21:00 2335

Advancing Healthcare Access: Genesis MedTech Teams Up with Silk Road Medical to Serve Patients affected by Carotid Artery Disease in China

WUXI, China, March 7, 2024 /PRNewswire/ -- Silk Road Medical (NASDAQ: SILK), a medical device company based inCalifornia USA and Genesis MedTech Group have signed an exclusive distribution agreement to introduce the TCAR® core products, ENROUTE® Transcarotid Neuroprotection System and ENROUTE® T...

2024-03-08 10:00 1136

VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China

SHANGHAI, March 7, 2024 /PRNewswire/ -- VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, today announced that the Biologics License Application (BLA) for Lonapegsomatropin (TransCon hGH) was accepted by the China National Medical Products Admi...

2024-03-08 10:00 1144

Chime Biologics Achieves ISO 27001 Certification to Strengthen Information Security in the CDMO Industry

WUHAN, China, March 7, 2024 /PRNewswire/ -- Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced that it has obtained ISO/IEC 27001:2022 certification on information security management systems. After passing rigorous reviews on all the items of...

2024-03-07 22:00 1146

Zylox-Tonbridge and Avinger Forge Strategic Partnership to Expand Disruptive OCT Solutions for Peripheral Vascular Interventions

HANGZHOU, China, March 7, 2024 /PRNewswire/ -- Zylox-Tonbridge (2190.HK, "the Company"), a leading medical device company in the peripheral and neurovascular interventional market inChina, today announced a new strategic partnership with Avinger, a commercial-stage medical device company developi...

2024-03-07 15:04 1129

Puritan's Pride Steadily Expands Its Global Influence, Securing a Leading Position Among Nutritional Brands

NEW YORK, March 6, 2024 /PRNewswire/ -- As global health awareness has increased, there has been a notable shift in people's focus from "treatment" to "prevention" of diseases. OnDecember 4, 2023, the International Self-Care Foundation and the Dietary Guidance Committee of the Chinese Aging Well ...

2024-03-06 21:37 989

OnCusp Therapeutics Announces First Patient Dosed in Phase 1 Trial of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

--CUSP06 is a CDH6-directed Antibody-Drug Conjugate (ADC) with a differentiated profile and potentially best-in-class activity-- NEW YORK, March 6, 2024 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innova...

2024-03-06 21:00 949

Akeso Announced the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-line Treatment of PD-L1 negative NSCLC

HONG KONG, March 6, 2024 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced the enrollment of the first patient in the registrational Phase III clinical study comparingCadonilimab (PD-1/CTLA-4 bispecific antibody) combined with chemotherapy versus Tislelizumab (PD-1 antibody) combined with ...

2024-03-06 18:07 1522

AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, March 5, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that the latest results from three preclinical stud...

2024-03-06 08:59 2554

Datasea Expects Approximately 1,128% Revenue Growth in 2024

BEIJING, March 5, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada corporation engaged in innovative business segments for Acoustics Intelligence and 5G-AI multimodal communication technology inChina and the US, issued guidance today for expecting a revenue o...

2024-03-05 23:45 2502

Laifen Launches the Laifen Wave Electric Toothbrush, a Revolutionary New Oral Health and Wellness Experience

Laifen's Newest Self-Care Innovation is Now Available to Purchase in the U.S. HONG KONG, March 5, 2024 /PRNewswire/ -- Laifen , a renowned leader in personal care appliances, is pleas...

2024-03-05 22:00 1012

WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment

SHANGHAI, March 5, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for outstanding performance in the 2023 Climate Change Assessment conducted by the global environ...

2024-03-05 21:00 1117

YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries

GAITHERSBURG, Md., March 5, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2024-03-05 21:00 2348

Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery

TAIPEI, March 4, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals (6838.TWO) and AimMax Therapeutics (United States) announced today that the U.S. Food and Drug Administration (FDA) has approved clobetasol propionate ophthalmic suspension 0.05% (APP13007), for the treatment of post-opera...

2024-03-05 06:55 1239

Neurophet introduces AI-powered brain imaging analysis technology at AD/PD 2024

- Showcases brain imaging analysis technology with key products Neurophet AQUA and Neurophet SCALE PET - Aims to commercialize ARIA analysis and amyloid-positive prediction technology SEOUL, South Korea, March 4, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company f...

2024-03-04 22:00 1050

ACROBiosystems Launches New Initiative to Support Cell and Gene Manufacturers

NEWARK, Calif., March 4, 2024 /PRNewswire/ -- ACROBiosystems, one of the leading providers of innovative tools and solutions used from discovery to the clinic, has announced a new corporate initiative to supportex vivo cell manufacturing and manufacturers of innovative cell and gene therapies. I...

2024-03-04 22:00 877

KCI, a subsidiary of Samyang Group, won 'Platinum Medal' in EcoVadis ESG Rating, Ranked in the Top 1% worldwide

* Evaluated firstly as a L'Oreal partner in 2013 and achieved the highest rating in 11 years * Efforts to establish an ESG committee, reinforce labor and human rights management, and improve management of partners SEOUL, South Korea, March 4, 2024 /PRNewswire/ -- Samyang Group announced that ...

2024-03-04 21:30 915

Landmark Clinical Approval for YOLT-201 Obtained by the NMPA

SHANGHAI, March 4, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, today announced the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has officially  approved the YOLT-2...

2024-03-04 20:00 369

Caliway Announced Orphan Drug Designation Granted to CBL-514 for the Treatment of Dercum's Disease

-       CBL-514 is the first and only drug to receive both Orphan Drug Designation and Fast Track designation for Dercum's disease treatment. NEW TAIPEI CITY, March 3, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the U.S. Food and Drug Administration (FDA) granted Orp...

2024-03-04 07:00 1027
123456 ... 251